339 related articles for article (PubMed ID: 27196753)
1. Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo.
Chen Z; Chen Y; Xu M; Chen L; Zhang X; To KK; Zhao H; Wang F; Xia Z; Chen X; Fu L
Mol Cancer Ther; 2016 Aug; 15(8):1845-58. PubMed ID: 27196753
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
3. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
4. Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo.
Yang K; Chen Y; To KK; Wang F; Li D; Chen L; Fu L
Exp Mol Med; 2017 Mar; 49(3):e303. PubMed ID: 28303028
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
6. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
[TBL] [Abstract][Full Text] [Related]
7. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro.
Hsiao SH; Lu YJ; Li YQ; Huang YH; Hsieh CH; Wu CP
Mol Pharm; 2016 Jun; 13(6):2117-25. PubMed ID: 27169328
[TBL] [Abstract][Full Text] [Related]
9. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells.
He D; Zhao XQ; Chen XG; Fang Y; Singh S; Talele TT; Qiu HJ; Liang YJ; Wang XK; Zhang GQ; Chen ZS; Fu LW
PLoS One; 2013; 8(1):e54181. PubMed ID: 23349819
[TBL] [Abstract][Full Text] [Related]
10. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
11. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
Mi YJ; Liang YJ; Huang HB; Zhao HY; Wu CP; Wang F; Tao LY; Zhang CZ; Dai CL; Tiwari AK; Ma XX; To KK; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2010 Oct; 70(20):7981-91. PubMed ID: 20876799
[TBL] [Abstract][Full Text] [Related]
12. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.
Zhao XQ; Xie JD; Chen XG; Sim HM; Zhang X; Liang YJ; Singh S; Talele TT; Sun Y; Ambudkar SV; Chen ZS; Fu LW
Mol Pharmacol; 2012 Jul; 82(1):47-58. PubMed ID: 22491935
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells.
Zhang XY; Zhang YK; Wang YJ; Gupta P; Zeng L; Xu M; Wang XQ; Yang DH; Chen ZS
Molecules; 2016 Sep; 21(9):. PubMed ID: 27649127
[TBL] [Abstract][Full Text] [Related]
14. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
Yang L; Li M; Wang F; Zhen C; Luo M; Fang X; Zhang H; Zhang J; Li Q; Fu L
Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
17. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Wu T; Chen Z; To KKW; Fang X; Wang F; Cheng B; Fu L
Biochem Pharmacol; 2017 Jan; 124():29-42. PubMed ID: 27816545
[TBL] [Abstract][Full Text] [Related]
18. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
van Hoppe S; Jamalpoor A; Rood JJM; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
Pharmacol Res; 2019 Aug; 146():104297. PubMed ID: 31175939
[TBL] [Abstract][Full Text] [Related]
19. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
[TBL] [Abstract][Full Text] [Related]
20. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo.
Zhang Y; Li C; Xia C; Wah To KK; Guo Z; Ren C; Wen L; Wang F; Fu L; Liao N
Cell Commun Signal; 2022 Sep; 20(1):142. PubMed ID: 36104708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
